

# Features of T2DM in adolescents with low titer of ICA and IAA

Irina Eremina<sup>1</sup>, Tamara Kuraeva<sup>1</sup>, Lubov Zilberman<sup>1</sup>, Valentina Peterkova<sup>1</sup>

<sup>1</sup>Endocrinology Research Centre, Moscow, Russian Federation

## Purpose.

To assess the prevalence of pancreatic autoantibodies (Ab) and their impact on the course of type 2 diabetes mellitus (T2DM) in adolescents.

## Subjects and Methods:

ICA, GADA, IA-2 and IAA were measured in 66 patients with T2DM. Depending on the presence of autoantibodies (Ab) patients were divided into 2 groups: Ab<sup>-</sup> and Ab<sup>+</sup>. HLA-typing was carried out in 45 patients. The secretion of C-peptide in the standard carbohydrate breakfast test (50 g carbohydrates) in the debut of the disease and after 1 year was studied.


## Results:

Specific Ab were detected in 15.2% (ICA - 9.1% and IAA – 6.1% in low titer (up to 20 IU/ml); GADA and IA-2 were not detected). Patients of 2 groups (Ab<sup>-</sup>, n=56, and Ab<sup>+</sup>, n=10) did not differ significantly in age of diagnosis, sex ratio, obesity degree, frequency of "acanthosis nigricans" (Table 1). The frequency of HLA-haplotypes of high risk T1DM in Ab<sup>+</sup> was higher (77.8% against 36.1%, p<0.05), but the frequency of HLA-genotypes of high risk T1DM in the two groups did not differ significantly. The level of HbA1c in the debut of DM was higher in Ab<sup>+</sup> (7.4% (7.0; 10.6) against 6.75% (6.1; 7.9), p<0.05), after 1 year HbA1c did not differ (6.4% (5.9; 7.8) and 6.1% (5.7; 6.8)). Basal level of C-peptide in the disease debut did not differ significantly (2,3 ng/ml (1,8; 4,0) in Ab<sup>+</sup> and 3.4 ng/ml (1.9; 4.4) in Ab<sup>-</sup>), the stimulated C-peptide level was higher by 120 min in Ab<sup>-</sup> (3.2 ng/ml (3.0; 8.4) versus 15.6 ng/ml (5.1; 17.2), p<0.05). After 1 year the secretion did not differ. Insulin therapy in the debut of the disease received 40% of Ab<sup>+</sup> and 25% - of Ab<sup>-</sup>, p=0.3. Insulin therapy was not needed in any patient minimum 1 year from the diagnosis.


**Table 1 – Characteristics of T2DM with and without Ab**

|                           | Ab- (n=56)        | Ab+ (n=10)      |
|---------------------------|-------------------|-----------------|
| Age of diagnosis, year    | 13,5 (11,5; 15,5) | 12,7 (11; 14)   |
| Males/females             | 0,7:1             | 1:1             |
| Family history of T2DM    | 62,7              | 90              |
| SDS BMI                   | 2,7 (1,6; 3,4)    | 2,4 (1,2; 3,2)  |
| Acantosis nigricans, %    | 52,2              | 37,5            |
| HbA1c, %                  | 6,75 (6,1; 7,9)   | 7,4 (7,0; 10,6) |
| Total cholesterol, mmol/l | 4,4 (3,5;4,9)     | 4,5 (4,4; 4,8)  |
| triglyceride, mmol/l      | 1,1 (0,97; 1,58)  | 1,5 (1,1; 1,6)  |
| LDL, ммоль/л              | 2,5 (2,1; 3,11)   | 2,7 (2,5; 3,3)  |
| HDL, ммоль/л              | 1,12 (0,98;1,3)   | 1,0 (0,8; 1,1)  |


**Pic.1 Secretion of C-peptide in onset of the disease**



**Pic.2. Secretion of C-peptide in a year from diagnosis**



**Pic.3 Therapeutic tactics**



## Conclusion:

The incidence of pancreatic Ab in adolescents diagnosed with DM2 was 15.2%. In Ab<sup>+</sup> patients in the debut of the disease, there is a lower secretion of C-peptide at a higher level of HbA1c, but after 1 year, the secretion of C-peptide increases, and HbA1c decreases to the level in patients Ab<sup>-</sup>. The presence of low titre ICA and IAA is not associated with the emergence of the need for insulin for 1 year minimum.